Advertisement

Surgery Newsletter

FDA Approves Targeted Tx for Metastatic NSCLC

Capmatinib indicated for patients with certain tumor mutations WASHINGTON — The FDA approved the kinase inhibitor capmatinib (Tabrecta) to treat adult patients with metastatic non-small cell lung cancer (NSCLC) with...

Read More

Advertisement

For latest news and updates
Email-id is invalid